Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers

Risultato della ricerca: Article

44 Citazioni (Scopus)

Abstract

BACKGROUND: Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients.PATIENTS AND METHODS: We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days.RESULTS: All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy.CONCLUSIONS: Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.
Lingua originaleEnglish
pagine (da-a)68-72
Numero di pagine5
RivistaAnnals of Oncology
Volume17
Stato di pubblicazionePublished - 2006

Fingerprint

oxaliplatin
gemcitabine
Biliary Tract Neoplasms
Combination Drug Therapy
Drug Therapy
Safety
Survival
Biliary Tract
Neutropenia
Palliative Care

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

@article{4d81418bee5b4fdc9c0bcc34b28ea0a9,
title = "Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers",
abstract = "BACKGROUND: Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients.PATIENTS AND METHODS: We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days.RESULTS: All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50{\%}. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5{\%}) suffered grade 3 neutropenia and three patients (12.5{\%}) grade 3 thrombocytopenia. Only two patients (8{\%}) suffered grade 3 neuropathy.CONCLUSIONS: Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.",
author = "Giovanni Tomasello and Valerio, {Maria Rosaria} and Giuseppe Cicero and Nicolo' Gebbia and Antonio Russo and Fabio Fulfaro and Giuseppe Badalamenti and Gaspare Gulotta and Santangelo and {Di Leo} and Verderame",
year = "2006",
language = "English",
volume = "17",
pages = "68--72",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers

AU - Tomasello, Giovanni

AU - Valerio, Maria Rosaria

AU - Cicero, Giuseppe

AU - Gebbia, Nicolo'

AU - Russo, Antonio

AU - Fulfaro, Fabio

AU - Badalamenti, Giuseppe

AU - Gulotta, Gaspare

AU - Santangelo, null

AU - Di Leo, null

AU - Verderame, null

PY - 2006

Y1 - 2006

N2 - BACKGROUND: Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients.PATIENTS AND METHODS: We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days.RESULTS: All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy.CONCLUSIONS: Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.

AB - BACKGROUND: Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients.PATIENTS AND METHODS: We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m(2) on day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8, every 21 days.RESULTS: All the 24 patients were evaluable for response and toxicity. According to RECIST criteria we observed one complete response and 11 partial responses for an overall response rate of 50%. Overall survival for all the patients on study was 12 months (range 2-30). According to WHO criteria, three patients (12.5%) suffered grade 3 neutropenia and three patients (12.5%) grade 3 thrombocytopenia. Only two patients (8%) suffered grade 3 neuropathy.CONCLUSIONS: Oxaliplatin and gemcitabine chemotherapy seems to be effective with a favorable safety profile in first-line chemotherapy of advanced biliary tract cancers.

UR - http://hdl.handle.net/10447/11445

M3 - Article

VL - 17

SP - 68

EP - 72

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -